Regenerative Medicine Market Growing At A CAGR Of 32.2% And To Target $39.32 Billion By 2023

Regenerative Medicine

Small molecules and biologics segment is projected to grow at the highest rate among the product type segment during the analysis period.

The increase in number of R&D activities conducted in association with the use of regenerative medicine for the treatment of various diseases majorly drive the market growth”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, October 8, 2020 /EINPresswire.com/ — UPDATE AVAILABLE ON-DEMAND

The report on the global regenerative medicine market highlights that the market is expected to reach $5,444 million by 2016, from $39,325 million in 2023, growing at a CAGR of 32.2% from 2017 to 2023. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups.

North America is the highest contributor in the regenerative medicine market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Currently, majority of the available treatments for degenerative or life-threatening diseases do not provide a cure or are palliative; however, regenerative medicines have the capability to replace or regenerate the tissues and organs that are injured or diseased. Moreover, the utilization of nanomaterials in wound care, drug delivery, and immunomodulation create growth opportunities for the regenerative medicines market.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/391

The market report includes a detailed analysis of the Covid-19 impact on the regenerative medicine market. Over the course of 2019–2027, the market is expected to show significant growth. However, the recent Covid-19 outbreak is likely to affect some of the business operations. The report includes an analysis of how Covid-19 has and will affect the industry, studying reliable sources, interviews of experts, and annual reports of the major market players. The report includes major drivers, restraints, and opportunities within the regenerative medicine market.

The major factors boosting the market growth include technological advancements in tissue and organ regeneration, increasing prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened growth avenues for the regenerative medicine market. However, stringent regulations, operational inefficiency, and high cost of regenerative medicine treatment are the key factors affecting the market growth. Furthermore, advancements in stem cell technology and achieving core competency in the emerging economies are expected to fuel the market growth. Developed nations have adopted technological advancements in tissue engineering and regenerative medicine sectors, which would aid the expansion of the global market.

The cell therapy segment accounted for a significant share of about three-fifth the overall regenerative medicine market in 2016 due to the widespread adoption of cell therapy for treatment of several diseases such as musculoskeletal, cardiovascular, oncology, wound healing, and others. Small molecules and biologics has emerged as the fastest growing segment during the forecast period as these biologics are classic active substances delivering better overall economic return. These molecules have revolutionized the treatment of specific diseases such as musculoskeletal diseases, cancer, rheumatoid arthritis, and non-healing wounds.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/391

Musculoskeletal and wound healing segment accounted for about three-fifth share of the application market in 2016. Cell therapies are used in the treatment of musculoskeletal diseases such as bone tissue replacement, cartilage, tendon, and ligament repair and replacement. In addition, osteoporosis is one of the most prevalent diseases that require tissue engineering therapies. More than 75 million people suffer from osteoporosis in Europe, the U.S., and Japan every year, which boosts the demand for regenerative medicines.

Geographically, North America accounted for majority of the share of the overall regenerative medicine market in 2016, and is expected to maintain this trend during the forecast period. This is attributed to high capital investment, high disposable income of patients, numerous clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products. However, Asia-Pacific is projected to be the fastest growing region throughout the analysis period due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets, such as India and China, to overcome the unmet medical needs in these countries.

The Major Key Players Are:

Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc.

Access Full Report @ https://www.alliedmarketresearch.com/regenerative-medicines-market

The Other prominent players Are:

Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.

Key Findings of the Regenerative Medicine Market:

• Small molecules and biologics segment is projected to grow at the highest rate among the product type segment during the analysis period.
• North America dominated global regenerative medicine market in 2016, and is projected to continue its dominance in future.
• China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.
• Biologically derived materials segment was the largest contributor among the material segments in 2016.
• The synthetic materials segment generated the highest revenue, and is expected to continue its dominance in future.

Similar Reports:

Precision Medicine Software Market Analysis and Industry Forecast, 2027

Nuclear Medicine Market Analysis and Industry Forecast, 2027

Nanomedicine Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Infant Incubator Market is Generating Revenue of $401 million by 2023, at CAGR 5.9% Growth Rate

Infant Incubator

The emergence of high-tech incubators such as double walled incubators, and incubators with thermal-neutral environment.

This has led to the sizeable market growth as the key players are constantly indulging in the R&D of incubators to bring innovation to the neonatal care devices that thereby drives the growth”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, October 8, 2020 /EINPresswire.com/ — UPDATE AVAILABLE ON-DEMAND

The report on the global infant incubator market highlights that the market is expected to reach $268 million by 2016, from $401 million in 2023, growing at a CAGR of 5.9% from 2017 to 2023. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups. The neonatal intensive care unit (NICU) incubator segment accounted for nearly three-fifths share of the total market in 2016.

The Covid-19 outbreak has severely affected every sector across the world. The patient numbers have been increasing every day and the majority of the countries are in complete lockdown. This has affected the supply chain and overall business operations. International trading has taken a significant downfall and has created uncertainty in the stock market. These factors have affected the infant incubator market.

The infant incubator report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/2727

Infant incubator is a biomedical device with a rigid box-like chamber, which provides humidity, warmth, and oxygen to the newborn in a controlled environment. Infant incubator improves infant survival rate by maintaining thermal stability within the chamber and providing an infection free environment to the infant. Technological advancements in the neonatal care devices has led to the emergence of advanced infant incubators such as infant incubators with controlled light environment, minimized heat loss, and incubators with microprocessor-based servo-controlled temperature systems.

The prime factors that drive the growth of the infant incubators market is increase in incidence of preterm birth rates. Moreover, growth in number of NICU admissions, and inflow of technologically advanced infant incubators has further accelerated the demand of infant incubators globally to initiate the proper treatment of infant at the earliest. However, the scarcity of NICU units globally and inflated cost of infant incubators hampers the growth of the market. Nevertheless, funding by government and private organizations toward development of neonatal healthcare facilities in emerging economies is expected to provide lucrative growth opportunities for the infant incubators market.

The transport infant incubator accounted for about one-third share of the total market in 2016. This is owing to the fact that transport infant incubator is used more commonly in emergency situations to transfer infant safely from one location to another within controlled environment. However, the neonatal intensive care unit (NICU) incubator is expected to register growth of CAGR 4.3% throughout the forecast period. This is due to the rise in the number of NICU installations by hospitals and high investment by key players in bringing innovation to infant incubators.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/2727

In terms of application, neonatal hypothermia dominated the market with nearly half of the market share in 2016. This is attributed to the fact that neonatal hypothermia is recognized as the key contributor to the mortality and morbidity risk of newborns. The neonatal intensive care units end user segment dominated the market with about two-fifths share in 2016. This is attributed to the high number of NICU admissions globally. They are also preferred as primary location for keeping premature baby for proper treatment. However, pediatric hospitals are expected to show fastest growth at a CAGR of 6.3% during the forecast period. This is owing to the increase in adoption of infant incubators in these hospitals.

In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the market and is expected to continue this trend. This is due to increase in adoption of infant incubators technologies and high incidences of preterm babies specifically in China, India, and the other developing economies. Moreover, rise in investments towards development of healthcare-information technology (HCIT) done by key players in the infant incubators field is the main reason for the growth of the market in Asia-Pacific region.

The Major Key Players Are:

• General Electric Company
• Atom Medical Corporation
• Natus Medical Incorporated
• Bistos Co., Ltd.
• Medicor Elektronika Zrt.
• Fanem Ltd
• Inspiration Healthcare Group plc
• Phoenix Medical Systems
• Drgerwerk AG
• Cobams plc.

Access Full Report @ https://www.alliedmarketresearch.com/infant-incubator-market

Key Findings of the Infant Incubator Market:

• The neonatal intensive care units end user segment is anticipated to grow with a CAGR of 6.0% during the forecast period.
• The U.S. was the highest shareholder in the North America infant incubators market in 2016 and poised to retain its lead from 2017-2023.
• The lower birth weight application registered fastest growth with a CAGR of 6.4% during 2017-2023. India is expected to grow at the remarkable rate of 6.5% during the forecast period.
• The birthing centers end user segment held remarkable position with one-sixth share in 2016, registering a CAGR of 5.4% from 2017-2023.

Similar Reports:

Infectious Disease Diagnostic Market Analysis and Industry Forecast, 2027

Laboratory Information System Market Analysis and Industry Forecast, 2027

Infection Surveillance Solutions Market Analysis & Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

OnRamp Bio and NanoString Announce Global Availability of ROSALIND® for nCounter Users

ROSALIND-Logo

Logo for ROSALIND, OnRamp’s cloud-based analysis platform that facilitates data visualization, exploration and collaboration.

ROSALIND-nCOUNTER-ANALYSIS

NanoString now offers global access to ROSALIND for all nCounter users as a preferred analysis solution for nCounter data

After a Successful Early Access Program, the ROSALIND Analysis Platform is Now Available to all nCounter Users

NanoString Technologies, Inc. (NASDAQ:NSTG)

ROSALIND enables users to extract insights from their data faster and easier. The combination of these technologies should decrease the time from sample to insight for our users.”

— Chad Brown, SVP of Sales and Marketing at NanoString

SEATTLE, WA, USA, October 8, 2020 /EINPresswire.com/ — NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, today announced a key milestone in their partnership to develop new analysis tools to accelerate research on NanoString’s nCounter® Analysis System. After successful completion of an Early Access Program announced in May, the parties are expanding access to new analysis capabilities to all nCounter users. The new analysis functionality is built into ROSALIND®, OnRamp’s cloud-based analysis platform that facilitates data visualization, exploration, and collaboration. NanoString will support ROSALIND as a preferred analysis solution for nCounter data and make it broadly available to users of the nCounter Analysis System.

“ROSALIND is an excellent complement to the nCounter System,” said Chad Brown, SVP of Sales and Marketing at NanoString. “nCounter enables data production faster and easier than other technologies on the market and ROSALIND enables users to extract insights from their data faster and easier. The combination of these technologies should decrease the time from sample to insight for our users.”

ROSALIND is a cloud platform that connects researchers to differential expression and pathway exploration in a highly collaborative environment. It enables users without formal bioinformatics training to explore their data deeply and extract meaningful insights rapidly. In addition to a streamlined, interactive user interface, ROSALIND enables researchers to compare across datasets and share insights with colleagues.

“We are very excited to open up ROSALIND to the full nCounter user base and help users complete their studies faster”, said Tim Wesselman, CEO of OnRamp Bio. “Never before has team-science and speed to result been more important, and the combination of nCounter, ROSALIND, and NanoString’s customer base of world-class researchers sets the stage for many exciting discoveries to come.”

To learn more about ROSALIND for nCounter visit https://www.onramp.bio/nanostring or join our 11/12 webinar where nCounter customer Canopy Biosciences demonstrates their use of ROSALIND to streamline analysis pipelines: https://event.on24.com/wcc/r/2751510/D38AA54EE13D1576634F2F88F32F6BCA

About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 3,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

About OnRamp BioInformatics, Inc.
OnRamp Bio is the San Diego genomics company that develops and maintains the ROSALIND® Discovery and Collaboration Platform designed specifically for Biologists and Life Science Researchers. By simplifying the complexity of bioinformatics and empowering scientists to directly interpret their datasets, ROSALIND focuses on time savings, accuracy, and consistency in the analysis of multi-omic data. OnRamp Bio was recognized as Best of Show at BioIT World and has been cited as a best practice for bioinformatics by Expert Review of Molecular Diagnostic. ROSALIND is globally deployed and trusted by leading pharma, biotech, and research institutions as a preferred platform for scientific discovery and collaboration.

For more information, please visit www.onramp.bio

ROSALIND is a registered trademark of OnRamp BioInformatics, Inc.

Jay Gerlach
OnRamp BioInformatics, Inc
+1 206-348-6957
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Former Google & Magic Leap execs raise $5 million for video conferencing product designed specifically for work meetings

Headroom logo

Headroom uses A.I. to make work meetings suck less

Current video-conferencing solutions may efficiently send pixels, but they deliver fatigue, frustration, and failed communication. We can do better,”

— Julian Green, Co-Founder of Headroom

SAN FRANCISCO, CA, USA, October 8, 2020 /EINPresswire.com/ — Work meetings can be brutal. To make them suck less, two former Google and Magic Leap executives are teaming up on a video conferencing product called Headroom that will use machine learning and computer vision technology to do things like take notes, summarize key moments, generate real-time interactive transcripts, recognize non-verbal cues like hand raising, a thumbs-up, or group confusion or excitement, and more. The new company was announced today in a Medium post by co-founder Julian Green.

Headroom is piloting the software with select participants, and is welcoming additional pilot users through its website www.goheadroom.com. The company has raised $5 million in seed funding from a number of well-respected investors, including Anna Patterson, Gradient Ventures; Evan Nisselson, LDV Capital; Jerry Yang, AME Cloud Ventures; Ash Patel, Morado Ventures; Anthony Goldbloom, Co-Founder and CEO of Kaggle.com; and Serge Belongie, Cornell Tech Professor of Computer Vision and Machine Learning.

Said co-founder Andrew Rabinovich, “Think about your last meeting: Was it actually necessary? Productive? Were you really engaged? Or too busy taking notes? Were people excited to be there? Or just showing their faces? Does anybody actually know?”

“Current video-conferencing solutions may efficiently send pixels, but they deliver fatigue, frustration, and failed communication. We can do better,” said co-founder Julian Green.

Headroom is a virtual meeting interface that empowers people to do what they do best — form relationships, think creatively, solve problems — while letting AI take care of the rest. Key features include:

Real-Time, Interactive Transcripts — The technology powers accurate, real-time transcripts that identify who is speaking. Participants can interact with this transcript, flagging important moments or points with a click. At the end of the meeting, the entire meeting transcript is available to participants, along with a summary of the important moments flagged during the meeting.

More Inclusive Meetings — Computer Vision can identify when participants look confused or excited, raise their hand to ask a question, or signal their agreement or disagreement with a thumbs up or down. Speakers can also be prompted when their share of speaking time grows unbalanced, or if someone hasn’t had a chance to collaborate.

Action Items — A new feature in development will automatically identify phrases like “Action Items” and generate a list of those to-dos at the end of a meeting.

Smart Recordings — Interactive video summaries of flagged moments allow participants to watch only highlights at a desired speed, rather than being stuck with original meeting time.

Meeting Understanding — Participants can search for specific keywords and topics in the transcript and watch the associated video replays.

More Secure Meetings — Business meetings are highly confidential, and securing that information is Headroom’s top priority. Users can control exactly who can see information generated from the platform. By default, all meetings are private and confidential, with only participants able to access transcripts, summaries, and recordings. Users have the option to prevent sharing, directly control permission access to individuals or groups, and to not record a meeting.

Headroom is co-founded by Julian Green and Andrew Rabinovich, both of whom have extensive experience in machine learning, computer vision tech, and creating products that are used by billions of people.

A successful entrepreneur, Julian Green has founded a number of startups, including Jetpac, which leveraged A.I. and deep learning to create travel recommendations based on an analysis of publicly available photos. Jetpac was acquired by Google in 2014. Following the acquisition, Green held a number of senior positions at Google running Computer Vision Products, including Google Cloud Vision API, which allows people to develop insights from their images in the cloud; Mobile Vision, the on-phone Computer Vision API; Google Lens for Augmented Reality Visual Search; and a number of deep tech projects at Alphabet’s Moonshot Factory X.

Andrew Rabinovich most recently led AI efforts at Magic Leap, a spatial computing company that bridges the gap between the physical and digital world with wearable technology. Before joining Magic Leap, Rabinovich spent seven years at Google where he worked on on a number of initiatives, including object recognition and scene understanding projects for photo-sharing app Picasa; helping to launch the first AR app for Android, Google Goggles; visual search in Google Photos; the Inception neural network architecture; and developing a recognition engine for estimating calories from images of food. In 2013 and 2014, together with his colleagues, Rabinovich won ImageNet challenges for fine grained object classification and general object classification and detection, respectively.

Scott Coriell
Peak Public Affairs
+1 8023531449
email us here


Source: EIN Presswire

Flow Cytometry Market will Reach $6.5 Billion at a 16.0% CAGR Globally by 2025

Flow Cytometry Market

cytometry market size is set to grow at a remarkable pace in the coming years, attributed to technological advancements and high adoption in various research.

PUNE, MAHARASHTRA, INDIA, October 8, 2020 /EINPresswire.com/ — Flow cytometry has various advantages over traditional analytical methods such as ELISA, which includes its ability to deliver precise and accurate results, and lesser time consumption at about same prices. The flow cytometry technology is widely used in various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV, and hematological malignancies. The rising count of patients suffering from HIV and cancer, and increasing use of flow cytometry in hospitals and diagnostic centers, has created an impending need for flow cytometry in the effective diagnosis as well as monitoring of diseases. The term flow cytometry as well as fluorescence-activated cell sorting are often interchangeable. FACS or fluorescence activated cell sorting used in flow cytometry have ensured a strong market future.

flow cytometry market size is set to grow at a remarkable pace in the coming years, attributed to technological advancements and high adoption in various research and diagnostic applications.Due to this, many researchers are still reluctant in adopting this technology in their research work. Moreover, advancing technologies that has brought complex instrumentation requires highly skilled personals to operate these instruments.

Download Sample PDF of Report@ https://www.alliedmarketresearch.com/request-sample/90

Leading market players Danaher Corporation (Beckman Coulter), Becton, Dickinson and Company, EMD Millipore, Sysmex Corporation, Affymetix Inc., Luminex Corporation, Thermo Fischer Scientific, Bio-Rad Laboratories, Inc., Miltenyi Biotec, Inc. and Agilent Technologies, among others provided in this report. These players have adopted various strategies including expansions, mergers & acquisitions, joint ventures, new product launches, and collaborations to gain a strong position in the industry.

Increasing needs to enhance precisions and produce faster results as well as need for compact devices are compelling the clinical and diagnostic organization to adopt innovative technologies. Though popularity has been gained in the application field of life science industry, the cost of the instrument is impeding the growth.

"Flow cytometry market is in developing phase. Enhancing precision in results and presence of numerous flow cytometry techniques such as multicolor and multi-parameter flow cytometry has acted as a strong foothold, assisting the market growth in majority of the developed economies and foresees high potential in the emerging economies such as Asia Pacific and Africa. These economies have high demand for better health care techniques at an affordable cost. Increasing aged population who need better healthcare, increase in chronic disease and need for better diagnosis and treatment are few driving factors that are impacting the flow cytometry market"

Immunotyping and signal transduction, for example, have been playing a significant role in medical diagnostics. However, conventional technologies used, have limited the accuracy and impacted the result deliverance time of the diagnosis performed. Improving therapeutic scenario is equally attracting focus on early diagnostic tools. Currently, many cancer types have various treatment options; however, this depends on the time of diagnosis and the stage of the cancer.

Flow Cytometry Market Key Benefits:-

• The study provides an in-depth analysis of the clinical flow cytometry market share, size with current and future trends to elucidate the imminent investment pockets in the market.

• The report provides a quantitative analysis through 2019-2025, which would enable the stakeholders to capitalize on prevailing market opportunities.

• The flow cytometry market analysis on an extensive level, by component, helps in understanding the components of the flow cytometer that are currently used along with the variants that would gain prominence in the future.

• Complete overview of Competitive intelligence highlights the business practices followed by leading market players across various geographies.

• SWOT analysis enables to study the internal and external environment of the leading companies for strategy formulation.

Flow cytometry has been one of the most prevalent technologies which offer solutions for most of the problems discussed above. Key factors restraining the market include high instrument costs and size, lack of awareness among probable users and need for trained personnel. Most of the users are not aware of the advanced development in the flow cytometry technology and believe that the instruments are space consuming, complex in use and are of high cost, thus affecting the market growth.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/90

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
+1 800-792-5285
email us here


Source: EIN Presswire

Capsule Endoscopy Systems Market Increasing Demand for Efficient Management Practices Report Till 2025

Capsule Endoscopy Systems Market

Capsule endoscopy is non-invasive technique that allows complete examination of gastrointestinal tract using wireless, disposable device known as video capsule

PUNE, MAHARASHTRA, INDIA, October 8, 2020 /EINPresswire.com/ — North America and Europe collectively accounted for around 83% of the capsule endoscopy systems market revenue in 2014 and are expected to maintain their lead throughout the forecast period. Large patient base, rising healthcare expenditure and quick adoption of innovative technologies are the key factors responsible for market growth in these regions. Key players profiled in this report includes- Given Imaging Inc., Olympus Corporation, IntroMedic Inc., CapsoVision Inc. and Chongqing Jinshan Science & Technology Group Co. Ltd

Small bowel diseases segment accounted for the highest revenue. This was primarily due to a large patient population suffering from the small bowel disease and established reimbursement for small bowel capsules.

Download Sample PDF of Report@ https://www.alliedmarketresearch.com/request-sample/701

Capsule endoscopy is an advanced non-invasive technique that uses wireless disposable video capsule, workstations and recorders for the diagnosis of gastrointestinal disorders such as peptic ulcers, Crohn's disease, obscure gastrointestinal bleeding (OGB) among others. The capsule aid in capturing images, which are transmitted to the recorders and analyzed through workstations and software.

Capsule endoscopy would gradually replace conventional gastrointestinal monitoring techniques, largely due to the non-invasiveness and convenience. Increasing popularity of varied capsule types such as small bowel, oesophagus and colon, growing aging population and rising incidences of gastrointestinal disorders, are some of the key factors that would largely drive the market growth. On the other hand, unclear reimbursement policies, stringent regulations and high cost of capsule endoscopy systems, would hamper the market growth.

CAPSULE ENDOSCOPY SYSTEM MARKET KEY BENEFITS:-

• The report provides a quantitative analysis of the current market and estimations during the period of 2019–2025, which would help in identifying the prevailing market opportunities.

• Capsule endoscopy market conditions have been comprehensively analyzed based on regions.

• Key market players within the capsule endoscopy market have been profiled in the report and their strategies have been thoroughly analyzed for understanding the competitive outlook of the market.

• Extensive analysis of the market has been conducted by closely monitoring the top contenders and following key product positioning within the market framework.

• Comprehensive analysis of factors that drive and restrict the growth of the global capsule endoscopy market has been provided in the report.

• Exhaustive analysis of the global capsule endoscopy market helps in understanding the types of capsule endoscopes, which are currently being used along with the recorder and work stations that would gain prominence in future.

Moreover, colorectal cancer is the third most commonly diagnosed disease and is also the third leading cause of deaths in the United States. Thus, a large patient base of gastrointestinal (GI) disease requires adequate diagnosis and monitoring. Given Imaging was the first company to develop capsule endoscopy model, which was introduced in the developed countries. The capsule endoscopy system has emerged as an effective management and diagnosis technique for GI diseases such as Crohn’s disease, colorectal cancer, obscure gastrointestinal bleeding, polyposis syndromes and small bowel tumors.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/701

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
+1 800-792-5285
email us here


Source: EIN Presswire

GOTO Copenhagen 2021

For Developers, by Developers

COPENHAGEN, CAPITAL REGION, DENMARK, October 8, 2020 /EINPresswire.com/ — GOTO Copenhagen is a leading software development conference designed for developers, team leads, architects, and project managers. As software developers and architects ourselves, we wanted to create a great social and learning experience.

Join us in Copenhagen on April 19-21 to take a look into the absolute latest and greatest development tools and methodologies. You’ll learn how to stay ahead of the technology curve while taking part in and being inspired by a global innovation movement full of explorers, pioneers and trendsetters.

Join us in Copenhagen on April 19-21 to take a look into the absolute latest and greatest development tools and methodologies. You’ll learn how to stay ahead of the technology curve while taking part in and being inspired by a global innovation movement full of explorers, pioneers and trendsetters.

Save 10% on ticket prices — register now with code 'einpresswire10' at www.gotocph.com

GOTO Copenhagen
GOTO Conferences
+45 87 32 87 87
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Global Animal Medicine Market Trends: Stem Cell Therapy To Aid In Healing Animal Injury

Animal Medicine Market Report 2020-30: COVID-19 Impact And Recovery

Animal Medicine Global Market Report 2020-30: COVID-19 Impact And Recovery

The Business Research Company’s Global Animal Medicine Market Report 2020-30: COVID-19 Impact And Recovery

LONDON, GREATER LONDON, UK, October 8, 2020 /EINPresswire.com/ — Veterinary pharmaceutical producers have started using stem cell therapy as an animal medicine due to its excellent capabilities of healing arthritis or animal injury in the veterinary healthcare market. Stem cell therapy is a process of injecting stem cell into the body of the animal to replace the damaged cells of the body. The injected stem cell is unspecialized and acquires the property of the cell that has to be replaced. It also divides itself into as many cells as required by the body. It enables to treat the bone and ligament injury, kidney and liver disease, and some kinds of skin diseases.

The global animal medicine market size is expected to decline from $38.9 billion in 2019 to $32.4 billion in 2020 at a compound annual growth rate (CAGR) of -16.8%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. The COVID-19 pandemic is affecting industries across the globe, including the animal sector. The restrictions on non-essential medical services coupled with slowed production of veterinary pharmaceuticals due to extended factory closures in various countries, shortage of APIs and other chemicals, and rise in prices of key ingredients are the key factors for this decline. The global animal medicine market size is then expected to recover and grow at a CAGR of 7% from 2021 and reach $50.3 billion in 2023.

North America was the largest region in the global animal medicine market, accounting for 58% of the total share in 2019. Asia Pacific was the second largest region accounting for 18% of the global animal medicine market. Africa was the smallest region in the global animal medicine market.

The animal medicine market consists of sales of animal medicine and related services by entities (organizations, sole traders and partnerships) that produce animal medicine to treat animal diseases. This industry includes establishments that produce veterinary pharmaceuticals such as veterinary vaccines, veterinary antibiotics, and other veterinary pharmaceuticals. It also includes establishments that produce medical feed additives and nutritional feed additives.

The global animal medicine market size is segmented by type into veterinary pharmaceuticals and feed additives. By type of animal, the market is segmented into livestock and companion animals. By end-use, it is segmented into veterinary hospitals, pharmacies and drug stores, and veterinary clinics. The subsegments covered include veterinary vaccines, veterinary antibiotics, veterinary parasiticides, others – veterinary pharmaceuticals, medical feed additives, and nutritional feed additives.

The major players in the global animal medicine market are Zoetis Inc, Boehringer Ingelheim GmbH, Bayer AG, Elanco Animal Health (Eli Lilly and Company), and Ceva Santé Animale.

Here Is A List Of Similar Reports By The Business Research Company:

Veterinary Pharmaceuticals Market – By Animal Type (Livestock, Companion Animal), By Type Of Pharmaceutical (Veterinary Parasiticides, Veterinary Vaccines, Veterinary Antibiotics, Others), By Administration Route (Oral, Others), By End Use, And By Region, Opportunities And Strategies – Global Forecast To 2030
(https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-market)

Medical Feed Additives Global Market Report 2020-30: Covid 19 Impact And Recovery
(https://www.thebusinessresearchcompany.com/report/medical-feed-additives-global-market-report)

Nutritional Feed Additives Global Market Report 2020-30: Covid 19 Impact And Recovery
(https://www.thebusinessresearchcompany.com/report/nutritional-feed-additives-global-market-report)

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Growth In Digital Diabetes Management Market At 26.27% To 2023 Will Be Driven By The Increasing Prevalence Of Diabetes

Digital Diabetes Management Market Report 2020-30: COVID-19 Growth And Change

Digital Diabetes Management Global Market Report 2020-30: COVID-19 Growth And Change

The Business Research Company’s Global Digital Diabetes Management Market Report 2020-30: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, October 8, 2020 /EINPresswire.com/ — The global digital diabetes management market is expected to decline from $6.09 billion in 2019 to $6.03 billion in 2020 at a compound annual growth rate (CAGR) of -1.02%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The global digital diabetes management market is then expected to recover and reach $12.13 billion in 2023 at a CAGR of 26.27%.

The increasing prevalence of diabetes is projected to propel the demand for digital diabetes management devices and related services, thereby increasing demand in the digital diabetes market. Diabetes is a leading cause of death with 30% of loss of life expectancy from diagnosis of diabetes. According to the European Society of Cardiology’s (ESC) global statistics on diabetes published in April 2019, approximately 4 million people under the age of 60 years die from diabetes every year. The prevalence of diabetes for the age group 20-79 years is predicted to increase to 9.9% to reach 628.6 million people with an expected growth of 48% by the end of 2045, globally. Digital diabetes management devices provide continuous care for diabetic patients and provide relevant data for further analysis.

Several companies in the smart diabetes management market are increasing attention on developing design-focused and AI-powered connected apps to enhance the user experience, which is gaining significant popularity in the digital diabetes management market. Key companies operating in the digital diabetes management market including OneDrop, Ascencia, and Dario are increasing their focus on developing their products as stylish gadgets rather than medical devices.

In June 2018, Medtronic plc and IBM Watson Health announced the launch of AI-powered Sugar.IQ smart diabetes management app, designed to improve and simplify daily diabetes management.

The digital diabetes management market consists of sales of digital diabetes management devices and related services. Digital diabetes management includes devices, apps, and software that manage blood glucose levels in the human body. These devices play a vital role in the care of diabetes patients with the management of patient’s blood glucose levels and controlling their conditions.

The global digital diabetes care market is segmented by product & service into devices, application, data management software & platforms, and services. By device type, the market is segmented into handheld devices and wearable devices. By end user, it is segmented into self/home healthcare, hospitals & specialty diabetes clinics, and others.

Here Is A List Of Similar Reports By The Business Research Company:

Diabetes Care Devices Global Market Report 2020-30: COVID-19 Implications And Growth
(https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-global-market-report-2020-30-covid-19-implications-and-growth)

Diabetes Therapies Market – By Segments (Injectables And Oral), Trends, Key Players, Opportunities And Strategies – Global Forecast To 2023
(https://www.thebusinessresearchcompany.com/report/diabetes-therapies-market)

Smart Insulin Pens Market Global Report 2020-30: Covid 19 Growth And Change
(https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-market-global-report-2020-30-covid-19-growth-and-change)

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Why COVID-19 Is a Once-In-A-Lifetime Opportunity for The Pharma Industry to Build a Positive Reputation

Caliber’s Global Pharma Reputation Report 2020

Top 3 changes in pharma company reputation scores following Covid-19, based on more than 13,000 interviews conducted in 17 countries (China, Brazil, USA, Canada, Russia and 12 European markets)

Caliber provides real-time analytics and strategy for brand & reputation management

Big Pharma saves lives, but its reputation suffers – paradoxically, due to lack of perceived relevance. A new study reveals COVID-19 offers a chance for change.

Big Pharma has been criticized for putting profit-making above providing affordable medicine. Our study shows COVID-19 can change this as people now turn to Big Pharma for vaccines and treatments.”

— Shahar Silbershatz, CEO of Caliber

COPENHAGEN, DENMARK, October 8, 2020 /EINPresswire.com/ — Global Pharma Study 2020 – a recently published independent study of the global reputation of pharmaceutical companies by Caliber – shows how COVID-19 affects the reputation for 67 global pharma companies. Novo Nordisk, Teva, and MERCK are the top scorers while AbbVie, Johnson & Johnson, and Bayer struggle.

What is even more interesting is that the study reveals that COVID-19 offers a unique chance for the pharma industry to prove its relevance and reset its troubled relationship with the global public opinion.

** Pharma Scores Low On “Relevance” – But Numbers Have Risen Through COVID-19
In most countries, respondents' lowest score to pharma companies is for Relevance, defined as “standing for something people can relate to.” Relevance is also the perception area most positively impacted by COVID-19, indicating the opportunity for the sector these days.

Asked for the one single issue for pharma companies to focus on to build relevance and improve their overall image, physicians from all over the world answered in unison: “Access & Affordability.”

“This is not surprising considering the criticism for putting profit-making above providing affordable medical help to low-income families and citizens in third world countries which the industry has received for the last 10 years. While the criticism might not always be fair, it is a fact and deeply rooted in the public opinion. Our survey shows that COVID-19 has the potential to change this as the public eye now turns to Big Pharma for an effective vaccine”, says Caliber CEO Shahar Silbershatz.

CEO of Eli Lilly David A. Ricks confirmed this when speaking on the company’s first-quarter conference call earlier this year: “With the world in dire need of COVID-19 drugs and vaccines, the biopharmaceutical industry has a once-in-a-generation opportunity to reset its reputation.”

** Well Known Companies are the Least Liked and Trusted
The Global Pharma Report 2020 also shows that familiarity plays a role, with the more well-known companies being less liked and trusted. In general, Small Pharma companies perform better than Big Pharma on all indicators in the study. The two areas where the advantage is the strongest are “Differentiation” and “Integrity”, where the average scores for Small Pharma and Big Pharma companies have a significant 3-point gap between them. As the study suggests, Small Pharma is generally perceived as more responsible than Big Pharma, which goes a long way towards explaining these companies’ reputational advantage. Interestingly, however, the smaller, local companies are also seen as more differentiated.

** Old People Do Not Trust Big Pharma
The Global Pharma Study 2020 also reveals that older people do not see the sector and its companies as being responsible, or as standing for something they can relate to. The paradox is apparent; the older people get, the more reliant they become on healthcare and medicine in general. It would be fair to expect older people to be more favorably disposed towards the pharma sector and its treatments, for which they should be increasingly thankful. Nevertheless, the study shows a significant 7-point difference in average Trust & Like Score between Millennials and Boomers. This is another challenge the pharma industry needs to address to better its reputation in the market.

** The Pharma Industry Has a Lot of Work to Do
“The pharma industry is a unique and fascinating one – but it must do better at explaining its complexity to its audiences. Pharma professionals can use the report to focus their efforts on the right areas, and the trend is already positive – but much work remains!” says Herbert Heitmann, former Chief Communication Officer for Bayer, who has written the foreword to the report.

The Global Pharma Study 2020 is based on more than 13,000 interviews conducted in 17 countries (China, Brazil, USA, Canada, Russia and 12 European markets) and the analysis of over 47,000 evaluations of 67 pharmaceutical companies in total, including 14 so-called “Big Pharma” companies. The study is based on Caliber’s Real-Time Brand & Reputation Tracker (RTT) platform that measures public perceptions of companies worldwide. RTT has been conducted by Caliber since 2016 and is answered daily by thousands of people all over the world through a digital questionnaire distributed online (CAWI). This report is based on results from 2019-2020. The full study can be downloaded here.

Shahar Silbershatz
Group Caliber ApS
+45 88 96 87 26
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire